All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GBP510
Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 09, 2020
Details:
CEPI will contribute up to $10 million towards the cost of a phase I/II study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GX-19
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Details:
Genexine expects to obtain full data from a Phase I trial of its DNA vaccine GX-19 late this year or early next year, while starting a Phase IIa study within this year and concurrent Phase IIb and III trials in the first half of next year.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Novavax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 13, 2020
Details:
SK bioscience will manufacture the vaccine antigen component for use in the final drug product globally during the pandemic period. NVX‑CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS‑CoV‑2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GX-19
Therapeutic Area: Infections and Infectious Diseases Product Name: GX-19
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
First domestic pharmaceutical company to have been approved for clinical phase 1/2a of GX-19, which is a DNA vaccine against COVID-19, by the Ministry of Food and Drug Safety.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
